Yurii Ostapenko
机构：National Cancer Institute · ORCID：0000-0002-9843-0230
发表论文 19 篇 · 总被引 1022 次 · h-index 6
代表论文
- Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC (2024 · New England Journal of Medicine · 被引 453)
- Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (2024 · Annals of Oncology · 被引 346)
- Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC (2025 · New England Journal of Medicine · 被引 136)
- Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma (2024 · Journal of Clinical Oncology · 被引 49)
- Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA (2025 · Journal of Thoracic Oncology · 被引 17)
- Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer) (2023 · Future Oncology · 被引 17)